PVP Labs Pte. Ltd. is a Singapore based biotechnology company that specializes in the development of innovative drugs. Our company was founded in January of 2016, however, we began research of peptide based pain management in 2010. Our research resulted in the development of Taphalgin, which is a replacement for Morphine, and can supplant Fentanyl and Oxycontin, Percocet, etc. Taphalgin is non-addictive, and does not exhibit any of the side effects associated with Morphine or Opioids.
PVP Arvidal is a powerful antivirus drug, that raises the immunity level in humans, and provides relief from various forms of ARVI (Acute Respiratory Viral Infections) Influenza, and other acute respiratory ailments. Arvidal has demonstrated an ability to prevent the development of severe forms of pulmonary infectious diseases, such as coronavirus infections and COVID-19 in particular. The direct antiviral activity and the powerful immuno-modulating effect of the drug make it possible to rely on the protection of the mucous tissues of the pulmonary system from viruses. The presence of regenerative functions, to some extent mediated by the immuno-modulating properties of the peptide, which significantly reduces the likelihood of developing pathological processes in the lungs and prevent the development of fibrotic lesions.
PVP continues to work with Peptides, and our approach to research continues to produce superior results. Our reach goes well beyond Singapore and South East Asia, and extends to the Middle East, Asia, Eurasia, Europe and the United States.
Approximately 40% of patients at intermediate stages of cancer, and 60 to 87% of patients with a generalized form of cancer, suffer from pain of varying intensity.
Morphine, and its derivatives, are strong analgesics and are widely used in clinical practice. However, their use is associated with serious side effects: physical and psychological dependence, tolerance, risk of respiratory depression, euphoria, CNS effects, etc.
All these problems have long ago made the development of morphine alternatives based on new biochemical principles a matter of great importance.
Our peptide-based analgesic, delivers strong pain relief, is long lasting, and does not exhibit the usual opioid side effects. Taphalgin possesses a wide therapeutic range; and maintains stability when stored for long periods.
Taphalgin. Key Benefits
Taphalgin can be used in a wide range of applications
A New way of producing clinically important biopharmaceuticals.
Acute Respiratory Viral Infections (ARVI) and Influenza
Problem: No universal treatments for influenza and ARVI currently exist
Solution to the Problem: creation of a safe, effective broad-spectrum antiviral drug
Regardless of the pathogen, the upper respiratory tract, where the most intensive reproduction of viruses takes place in the epithelial cells, acts as the entry point for the infection.
The causative agents of ARVI are spread through airborne droplets, when coughing, sneezing, talking and through contaminated household items.
Arvidal– an antiviral immunotropic spray
A Drug based on one of the synthetic derivatives of an endogenous peptide of the enkephalin group, which has a wide range of regulatory capabilities; in particular, affecting the normalization of the biological functions of the human body.
The drug has both a direct antiviral effect and has a pronounced ability to stimulate factors of local and systemic immunological protection when administered as a spray through the nose and mouth.
It has both local and systemic effects for increasing the activity of the immune system, in particular, innate immunity, and, as a result, stimulating the protective mechanisms of adaptive immunity. It enhances the activity of the phagocytic immunity (macrophages and neutrophils), as well as the activity of natural killer cells. Stimulates the production of endogenous interferons.
It shows the ability to suppress excessive synthesis of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), reduces the degree of intoxication and suppresses other manifestations of the inflammatory cascade.
It has a powerful effect for suppressing the action of pathogens of respiratory diseases. It has both a prophylactic effect when one is at risk of contracting a disease, and a pronounced therapeutic effect. When administered intra-nasally, it is characterized by antiviral and immunomodulatory effects comparable to intramuscular administration, which is especially important for clinical use.
Reduces the intensity of symptoms and pain during the development of the disease.
Application in the early stages of the development of the disease or preventively, prevents a person from getting sick. In the later stages of development of the disease, it enables the patient to experience a milder form of the disease, thereby accelerating the elimination of residual effects from colds.
Compatibility profile of the drug allows its use both as monotherapy, and in combination with other drugs.
Due to a sharp increase in the concentration of neutrophils and the activity of innate immunity in the focus of infection, the reproduction of pathogens is stopped in the early stages of the disease. ARVI severity is reduced by inhibiting the development of secondary complications in the form of bacterial acute respiratory infections during influenza. Another established property of the drug is the regenerative effect with local and systemic administration. This property allows to reduce damage to lung tissue during the development of severe forms of the disease.
Presented in a convenient dosage form - nasal spray. The patient sprays the 0.1 - 0.5% aqueous solution in the nasal cavity and inhaling, or by applying to the area of the throat and oral cavity through the mouth.
In pronounced cases of the disease with involvement of the upper respiratory tract and lungs, the aerosol could be administered on an outpatient basis by inhalation through an compressor or ultrasonic nebulizer.
Arvidal – Safe to use
Arvidal does not cause abnormalities of the cardiovascular system, no pathological changes in the ECG were detected. Not accompanied by changes in hematological, biochemical and hormonal parameters.
No local toxicity or local irritating action.
The drug belongs to toxicity class VI "Relatively safe substances".
No cumulative effects, addiction or dependence.
Dalardenol. A peptide-based burn treatment and wound healing spray
Dalardenol is a burn treatment and wound healing agent that can be directly applied to the affected area, that acts on various mechanisms contributing to the healing of wounds of various aetiologies The principle of a unified topical and systemic therapy that underpins the treatment of patients with thermal burns. Special emphasis on topical treatment, which is aimed at the thorough healing of burn wounds and early restoration of the skin. Moreover, introduction of advanced treatment options such as reconstructive surgery and skin grafts or bio-membranes have increase demand.
Due to rising patient concerns regarding aesthetic appearance is a major factor attributed to the rising need for a drug such as Dalardenol. Furthermore, advantages in wound treatment, which are associated with the use of biologics, such as accelerated wound healing, are cost efficient, will result in a shorter hospital stay.
Functionality and Effectiveness
Dalardenol is a drug based on a synthetic derivative of an endogenous peptide of the enkephalin family, which has a wide range of regulatory effects on tissue regeneration in wound and burn areas. It provides pain relief, reduces inflammation, shields skin lesions from microorganisms, stimulates skin cell metabolism and ensures scare-free wound healing.
The application of Dalardenol is in the form an externally applied Spray and /or as a gel. The spray form allows large wound and burn surfaces to be quickly treated under virtually any conditions. The use of drug on the 1st day of injury, reduces the severity of redness of the skin. Moreover, Dalardenol is significantly superior to Dexpanthenol in reducing hyperaemia over time.
The problem and relevance of our drug development The outbreak of viral infectious diseases has constantly accompanied humanity. Acute respiratory viral infections (ARVI) are currently the most common type of infectious diseases. According to WHO, there are approximately 300 respiratory viral pathogens, and the viral threat continues to grow. The emergence of new SARS-CoV-2 andRead more about PVP Labs discovers – a life-saving solution that can be used during the early phase of viral infections, to assist humanity in its’ struggle against the viral spread[…]